A Randomized, Open-Label Study to Assess Efficacy of Weekly Assumption of Cholecalciferol versus Calcifediol in Older Patients with Hypovitaminosis D
The aim of this single-center, open-label, randomized controlled study was to evaluate which formulation of vitamin D-between cholecalciferol and calcifediol-is most effective in the treatment of hypovitaminosis D in older adults. Demographic characteristics, clinical history, and comprehensive geriatric assessment were recorded at admission. Eligible patients were randomly assigned an equivalent vitamin D supplement, either with cholecalciferol or calcifediol, from the time of hospital admission to three months after discharge. Among the 140 older patients included (mean age 83 ± 6.6 years, 57.8% females), 69 received cholecalciferol and 71 received calcifediol. The mean plasma values of 25-hydroxyvitamin D3 (25OH-vitamin D3) found at the time of enrollment were 16.8 ± 9.9 ng/mL in patients receiving cholecalciferol and 18.8 ± 13.3 ng/mL in those treated with calcifediol (p = 0.31). At the three month follow-up, the mean concentration of 25OH-vitamin D3 was significantly higher in patients treated with calcifediol than in those receiving cholecalciferol (30.7 ± 8.4 vs. 45.4 ± 9.8 ng/mL, respectively; p < 0.001). Supplementation with either cholecalciferol or calcifediol effectively results in reaching the optimal circulating values of 25OH-vitamin D3 in older patients suffering from hypovitaminosis D. However, supplementation with calcifediol led to average circulating values of 25OH-vitamin D3 that were significantly higher (over 50%) than those obtained with cholecalciferol.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Geriatrics (Basel, Switzerland) - 7(2022), 1 vom: 07. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Okoye, Chukwuma [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Calcifediol |
|---|
| Anmerkungen: |
Date Revised 28.01.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/geriatrics7010013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336110278 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336110278 | ||
| 003 | DE-627 | ||
| 005 | 20231225231406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/geriatrics7010013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336110278 | ||
| 035 | |a (NLM)35076537 | ||
| 035 | |a (PII)13 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Okoye, Chukwuma |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Randomized, Open-Label Study to Assess Efficacy of Weekly Assumption of Cholecalciferol versus Calcifediol in Older Patients with Hypovitaminosis D |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.01.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The aim of this single-center, open-label, randomized controlled study was to evaluate which formulation of vitamin D-between cholecalciferol and calcifediol-is most effective in the treatment of hypovitaminosis D in older adults. Demographic characteristics, clinical history, and comprehensive geriatric assessment were recorded at admission. Eligible patients were randomly assigned an equivalent vitamin D supplement, either with cholecalciferol or calcifediol, from the time of hospital admission to three months after discharge. Among the 140 older patients included (mean age 83 ± 6.6 years, 57.8% females), 69 received cholecalciferol and 71 received calcifediol. The mean plasma values of 25-hydroxyvitamin D3 (25OH-vitamin D3) found at the time of enrollment were 16.8 ± 9.9 ng/mL in patients receiving cholecalciferol and 18.8 ± 13.3 ng/mL in those treated with calcifediol (p = 0.31). At the three month follow-up, the mean concentration of 25OH-vitamin D3 was significantly higher in patients treated with calcifediol than in those receiving cholecalciferol (30.7 ± 8.4 vs. 45.4 ± 9.8 ng/mL, respectively; p < 0.001). Supplementation with either cholecalciferol or calcifediol effectively results in reaching the optimal circulating values of 25OH-vitamin D3 in older patients suffering from hypovitaminosis D. However, supplementation with calcifediol led to average circulating values of 25OH-vitamin D3 that were significantly higher (over 50%) than those obtained with cholecalciferol | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a calcifediol | |
| 650 | 4 | |a cholecalciferol | |
| 650 | 4 | |a hypovitaminosis D | |
| 650 | 4 | |a older patient | |
| 650 | 4 | |a vitamin D | |
| 700 | 1 | |a Calsolaro, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Niccolai, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrese, Alessia Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Franchi, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Rogani, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Coppini, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Morelli, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Caraccio, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Monzani, Fabio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Geriatrics (Basel, Switzerland) |d 2015 |g 7(2022), 1 vom: 07. Jan. |w (DE-627)NLM273273493 |x 2308-3417 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:1 |g day:07 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/geriatrics7010013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 1 |b 07 |c 01 | ||